Oncimmune provides ImmunoINSIGHTS™, a high‑throughput, bead‑based multiplex assay that profiles autoantibody repertoires against a library of over 9,000 human and multi‑species antigens using less than 50 µL of serum or plasma. The platform combines Luminex xMAP® technology, automated robotic workflows, and proprietary bioinformatics to generate reproducible biomarker signatures for patient stratification, target identification, and safety monitoring across oncology, autoimmune, infectious and metabolic disease programs.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biopharma and clinical researchers often lack comprehensive, high‑throughput tools to profile autoantibody repertoires across the full human proteome, making it difficult to discover reliable biomarkers for disease stratification, treatment response, and immune‑related adverse events.
Solution
Oncimmune offers ImmunoINSIGHTS™, a multiplexed bead‑based assay platform that interrogates over 9,000 human and multi‑species antigens using less than 50 µL of serum or plasma. The system leverages Luminex xMAP® technology combined with automated robotic workflows to deliver high‑throughput, reproducible measurements of IgG, IgM, and IgA autoantibodies. Integrated bioinformatics and proprietary machine‑learning algorithms transform raw assay data into actionable biomarker signatures, supporting applications such as target identification, patient stratification, and prediction of immune‑related adverse events. Customizable panels and multi‑omics data integration enable tailored studies across oncology, autoimmune, infectious, and metabolic disease areas, accelerating precision‑medicine development.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as academic and contract research organizations conducting biomarker discovery, clinical trial enrichment, or safety monitoring for oncology, autoimmune, infectious, and metabolic disease programs.
Features
- Access to the world’s largest curated antigen library (9,000+ human and multi‑species proteins) for comprehensive autoantibody profiling
- Minimal sample requirement (<50 µL serum, plasma, or other biofluid) suitable for scarce clinical specimens
- High‑throughput bead‑based multiplex assay (Luminex xMAP®) capable of detecting hundreds of targets per sample
- Automated robotic sample handling for large study cohorts with consistent reproducibility
- Custom panel design allowing inclusion of disease‑specific antigens, IgG/IgM/IgA isotypes, and pathway‑focused markers
- Advanced bioinformatics pipeline with proprietary algorithms, statistical workflows, and multi‑omics integration to generate predictive biomarker models
- Secure cloud‑based data storage and analytics dashboard for collaborative review and export of results